1. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Issue 9 (13th May 2021) Authors: Mease, Philip J; Chohan, Saima; Fructuoso, Ferran J Garcia; Luggen, Michael E; Rahman, Proton; Raychaudhuri, Siba P; Chou, Richard C; Mendelsohn, Alan M; Rozzo, Stephen J; Gottlieb, Alice Journal: Annals of the rheumatic diseases Issue: Volume 80:Issue 9(2021) Page Start: 1147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LB0002 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. (June 2019) Authors: Mease, Philip J; Chohan, Saima; Fructuoso, Ferran J García; Chou, Richard C; Nograles, Kristine E; Mendelsohn, Alan M; Luggen, Michael E Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗